1.1.1 The amyloid cascade hypothesis and its 30-year dominance

1.1.2 What the lecanemab CLARITY-AD trial actually showed

1.1.3 The donanemab TRAILBLAZER-ALZ 2 results and ARIA-E rates

1.1.4 Aducanumab's withdrawal and the graveyard of failed amyloid drugs

1.1.5 The Rush autopsy series — pure Alzheimer's vs. mixed pathology

1.1.6 Jellinger's reviews and the oldest-old (74–93% mixed)

1.1.7 The Honolulu-Asia Aging Study and microscopic infarcts

1.1.8 HUNT4 70+ — Alzheimer's pathology in 23.5% of cognitively unimpaired

1.1.9 STRIVE-2 and the cerebrovascular contribution to dementia

1.1.10 The economic asymmetry: $26,500 vs. $1,200 per year

1.2.1 Gray matter, white matter, and the 40–50% volume share

1.2.2 Why white matter is metabolically vulnerable

1.2.3 The penetrating arteriole supply and the hydraulic dead zones

1.2.4 STRIVE-2's six imaging features of cSVD

1.2.5 Newer features: cortical microinfarcts, superficial siderosis, BBB permeability

1.2.6 Mechanism 1: endothelial dysfunction

1.2.7 Mechanism 2: blood-brain barrier breakdown

1.2.8 Mechanism 3: chronic hypoperfusion

1.2.9 Mechanism 4: glymphatic dysfunction

1.2.10 Hypertensive arteriolosclerosis vs. cerebral amyloid angiopathy

1.3.1 What a typical primary care visit captures (and misses)

1.3.2 WMH prevalence: 11–15% in midlife, 87% by late 60s, ~100% over 80

1.3.3 The MMSE's insensitivity to vascular changes

1.3.4 The MoCA's strengths and limits

1.3.5 Trail Making B, Stroop, Digit Symbol — what's actually sensitive

1.3.6 The 28/30 patient who can't manage finances

1.3.7 Why office BP captures the least informative part of the curve

1.3.8 The screening battery's calibration to overt disease

1.4.1 Stern's reserve framework and the 2020 consensus paper

1.4.2 Brain reserve (hardware) vs. cognitive reserve (software)

1.4.3 The Brickman 2011 study — multiplicative interaction with WMH

1.4.4 The "70% damage before symptoms" claim — where it comes from

1.4.5 The Parkinson's origin (Fearnley & Lees) vs. Alzheimer's data

1.4.6 Vermunt's 10–20 year preclinical phase estimate

1.4.7 The sigmoidal tipping-point model

1.4.8 Why early intervention compounds across decades

2.1.1 The healthy 10–20% nocturnal dip and what drives it

2.1.2 The four dipping categories: dipper, non-dipper, reverse dipper, extreme dipper

2.1.3 Reverse dipping as the highest-risk pattern (Kario, Ohasama)

2.1.4 Non-dipping prevalence in special populations (Black, OSA, diabetes)

2.1.5 Why the dip blunts: sympathetic, parasympathetic, and renal mechanisms

2.1.6 Why office BP cannot detect non-dippers

2.1.7 IDACO database findings: nocturnal BP outperforms daytime

2.1.8 Threshold definitions: ACC/AHA 110/65 vs. European 120/70

2.2.1 Why we can't find the "2 AM micro-burst" in peer-reviewed literature

2.2.2 The actual nocturnal pressure curve — trough between 2–4 AM

2.2.3 Kario's morning surge data: 19% vs. 7.3% stroke incidence

2.2.4 REM-related sympathetic surges and their timing

2.2.5 Apnea events as a cause of transient pressure spikes

2.2.6 Maracaibo Aging Study — reverse dippers and periventricular WMH

2.2.7 Henskens, Nakanishi, and the cross-cohort consistency

2.2.8 Microbleeds, BBB leakage, and the "leaky roof" mechanism

2.3.1 HypnoLaus prevalence — 83.8% of men have AHI ≥5

2.3.2 The apnea cascade: surge, desaturation, arousal

2.3.3 Yaggi 2005 NEJM — OSA roughly doubles stroke/death risk

2.3.4 Yaffe 2011 — sleep-disordered breathing and incident MCI/dementia

2.3.5 Why AHI is the wrong metric: hypoxic burden (Azarbarzin)

2.3.6 The MrOS finding — hypoxic burden, not AHI, predicts mortality

2.3.7 Why the SAVE trial of CPAP was negative

2.3.8 The "AHI of 5 is still too high" claim — partial support

2.3.9 Snoring without apnea — Lee 2008 and carotid atherosclerosis

2.3.10 The bed partner asymmetry — observation as data

2.4.1 The biology of the dip — anticipation of demand

2.4.2 Cortisol's daily cycle and pressure interaction

2.4.3 Melatonin, vasodilation, and sleep onset

2.4.4 Aldosterone, RAS, and renal sodium handling

2.4.5 Sympathetic withdrawal in slow-wave sleep

2.4.6 Late-night habits that prime the system: sodium, alcohol, caffeine, light

2.4.7 The morning surge and the first two hours after waking

2.4.8 Why "is my BP controlled?" is the wrong question

3.1.1 Debette/Seshadri/DeCarli 2011 — midlife hypertension accelerates WMH

3.1.2 Maillard 2012 — pressure effects in young adults averaging 39

3.1.3 No "safe zone" below the conventional hypertension threshold

3.1.4 The Spartano fitness work — 1 SD = 1 year of brain aging

3.1.5 Petrea — sustained midlife-to-late-life hypertension and cumulative exposure

3.1.6 Satizabal 2016 NEJM — 20% per decade dementia decline

3.1.7 What Framingham did NOT measure (ambulatory/nocturnal BP)

3.1.8 The synthesis with Ohasama, IDACO, J-HOP, PAMELA, Maracaibo, CABL

3.2.1 What WMH look like on T2/FLAIR

3.2.2 Periventricular vs. deep WMH — different histology, different meaning

3.2.3 The Fazekas scale (0–3) and the Scheltens alternative

3.2.4 At what burden do they matter? Debette/Markus BMJ meta-analysis

3.2.5 PROGRESS — 1.1 to 9.1 per 100 person-years gradient

3.2.6 LADIS — severe WMH doubles transition to dependent living

3.2.7 The 90-day reversal claim — what the data actually show

3.2.8 Wardlaw, Al-Janabi, and PROGRESS treatment data

3.2.9 The honest summary: stabilization over years, not reversal in 90 days

3.3.1 The Hedman canonical numbers — 0.2% to 1% per year by decade

3.3.2 The "almond" comparison — why it understates the loss

3.3.3 Brown & Markus 2021 — WMH growth ratios of 4–10×

3.3.4 The CARDIA study — 3.3-year brain age offset, not 3× rate

3.3.5 SPRINT MRI substudy — 0.54 cc smaller WMH increase

3.3.6 What "2 to 10 times faster" actually means in practice

3.3.7 NeuroQuant and quantitative volumetrics for tracking

3.4.1 The frontal-prefrontal circuit and its arteriole supply

3.4.2 Superior longitudinal fasciculus, anterior corpus callosum, thalamic radiations

3.4.3 Why vascular impairment looks different from Alzheimer's

3.4.4 Bartzokis on myelin integrity and processing speed

3.4.5 Filley's "white matter dementia" framework

3.4.6 The Montero-Odasso triad: executive + gait + depression

3.4.7 Apathy (22–56%) vs. depression (~22%)

3.4.8 Marche à petits pas and the magnetic gait

3.4.9 The Sharma & Smith 2023 review — gait and WMH

3.4.10 The "disconnect syndrome" framing (Catani, ffytche)

4.1.1 Why some 3 AM awakenings are vascular

4.1.2 What the awakenings cluster with: apnea, REM, fragmentation

4.1.3 Sabia/Whitehall II — sleeping ≤6 hours at 50 raises dementia risk

4.1.4 The U-shaped sleep duration curve

4.1.5 Lim 2016 — sleep fragmentation and WMH

4.1.6 The glymphatic system: Iliff 2012 and the basics

4.1.7 Xie 2013 — 60% interstitial expansion during sleep

4.1.8 Fultz 2019 — CSF flow coupled to slow-wave sleep

4.1.9 Mestre 2018 — hypertension impairs perivascular pumping

4.1.10 Caveats: rodent vs. human, DTI-ALPS limitations

4.1.11 The "cold hands, cold feet" claim — what it does and doesn't mean

4.2.1 Why the patient sees less than the partner

4.2.2 Episodic memory preservation in early vascular impairment

4.2.3 The repeated story and source memory

4.2.4 The sentence-finishing reflex

4.2.5 Personality flattening and bandwidth cost

4.2.6 Why office screens miss this profile

4.2.7 The "you've been forgetting things" conversation as data

4.3.1 Why "senior moment" is a corrosive frame

4.3.2 The pattern of features that co-occur

4.3.3 Difficulty returning to a task after interruption

4.3.4 Slowed comprehension despite preserved recognition

4.3.5 Cognitive fatigue and the 3 PM wall

4.3.6 Retrieval-type vs. storage-type word-finding difficulty

4.3.7 The gait connection and shared anatomy with cognition

4.3.8 Forgetting your keys vs. losing the map

4.4.1 What a reasonable evaluation includes

4.4.2 History — including bed partner and family observations

4.4.3 Cognitive testing that captures executive function

4.4.4 24-hour ambulatory blood pressure monitoring

4.4.5 Sleep study indications and types

4.4.6 Brain MRI protocol — what to ask for

4.4.7 The Fazekas grade in the report

4.4.8 NeuroQuant and quantitative volumetrics

4.4.9 APOE genotyping and its insurance implications

4.4.10 Honest expectations: stabilization, not return to baseline

4.4.11 The "watching and waiting" that is really "watching and losing"

5.1.1 AARP 2026 — 59 million caregivers, 49.5 billion hours, $1 trillion

5.1.2 Alzheimer's Association — 12 million dementia caregivers, $446.3B

5.1.3 Pew's sandwich generation definition

5.1.4 The age distribution: 54% of 40s, 36% of 50s

5.1.5 The Lei/Maust upward-care finding

5.1.6 Sandwich caregivers' financial and emotional difficulty (2× and higher)

5.1.7 40% depression rate, 60% high emotional stress

5.1.8 Schulz/Beach 1999 — the 63% mortality finding

5.1.9 Roth's complication and the strain-subgroup interpretation

5.1.10 The "long goodbye" trajectory and its open-endedness

5.2.1 The 2024 Genworth/CareScout numbers — home aide, assisted living, nursing

5.2.2 Memory care premiums and regional variation

5.2.3 The $400,000 lifetime estimate and the 70% family share

5.2.4 Why Medicare doesn't cover long-term care

5.2.5 Medicaid spend-down to ~$2,000

5.2.6 Aboulafia 2025 — 61.8% Medicaid transition by year 4

5.2.7 Long-term care insurance and the shrinking market

5.2.8 Hybrid life-LTC products

5.2.9 VA Aid & Attendance, Medicaid waivers, reverse mortgages

5.2.10 The realistic planning question

5.3.1 MetLife 2011 — $324K women, $284K men in lifetime losses

5.3.2 Urban Institute DYNASIM4 — $295K to $420K

5.3.3 Quit rates, leave rates, and reduced hours

5.3.4 Lost insurance, retirement savings, Social Security

5.3.5 The gender disparity and women's downstream risk

5.3.6 The third-generation ripple to grandchildren

5.3.7 Aging with dignity vs. aging as a liability

5.4.1 Honest framing — prevention shifts probability, not certainty

5.4.2 The Lancet Commission 2024 — 40–45% modifiable

5.4.3 The full modifiable risk factor list (in order of impact)

5.4.4 Why hearing loss matters more than people realize

5.4.5 The intergenerational economic case

5.4.6 The "hero's exit" framing and remaining yourself

6.1.1 The 2025 AHA/ACC office target of <130/80

6.1.2 24-hour ABPM as the gold standard

6.1.3 What ABPM measures and how Medicare covers it

6.1.4 Why to ask if your clinician doesn't routinely order it

6.1.5 Validated home BP monitors with nighttime modes

6.1.6 The HOPE Asia / J-HOP home protocol

6.1.7 Cuffless wearables — the 2025 AHA position

6.1.8 The Aktiia/Hilo Band and FDA clearance

6.1.9 Apple Watch, Samsung, Oura, Whoop — what they can and can't do

6.1.10 Home pulse oximetry as a screening tool

6.1.11 Home sleep apnea testing vs. in-lab polysomnography

6.2.1 The unglamorous high-evidence interventions

6.2.2 SPRINT-MIND in detail — 19% MCI, 17% composite reductions

6.2.3 The dementia endpoint nuance and early stopping

6.2.4 SPRINT MRI substudy — less WMH increase

6.2.5 Drug class — magnitude of reduction vs. specific agent

6.2.6 The chronotherapy controversy

6.2.7 Hygia Trial and the Expression of Concern

6.2.8 TIME study — no difference between morning and evening dosing

6.2.9 The 2025 international consensus position

6.2.10 L-citrulline and L-arginine — the retracted Mahboobi meta-analysis

6.2.11 The 30-minute pre-bed nitric oxide window (no peer-reviewed basis)

6.2.12 Beetroot and dietary nitrate

6.2.13 Magnesium

6.2.14 Omega-3 fatty acids

6.2.15 Vitamin K2

6.2.16 B vitamins and homocysteine

6.2.17 Curcumin, resveratrol, and other polyphenols

6.2.18 The honest hierarchy — 10–20 mmHg vs. 2–7 mmHg

6.3.1 Adherence as the most modifiable variable

6.3.2 Medicare's regulatory minimum (4 hr × 70%) vs. optimal targets

6.3.3 Weaver's dose-response: 4 / 6 / 7.5 hours

6.3.4 The metrics on a CPAP cloud report

6.3.5 Residual AHI, mask leak, oxygen saturation

6.3.6 Why APPLES showed only mild benefit

6.3.7 Why SAVE was negative (3.3 hr/night adherence)

6.3.8 Dunietz 2021 — PAP adherence and Alzheimer's risk

6.3.9 Mandibular advancement devices

6.3.10 Positional therapy

6.3.11 Hypoglossal nerve stimulation (Inspire)

6.3.12 Weight loss and the AHI-per-BMI relationship

6.3.13 Side-sleeping and possible glymphatic effects

6.4.1 The six-priority synthesis

6.4.2 Priority 1 — Get the actual numbers

6.4.3 Priority 2 — Control blood pressure aggressively but tolerably

6.4.4 Priority 3 — Treat sleep apnea if present

6.4.5 Priority 4 — Build the lifestyle stack

6.4.6 The FINGER multidomain intervention

6.4.7 Aerobic exercise and Erickson's hippocampal RCT

6.4.8 Mediterranean / DASH dietary patterns

6.4.9 The MIND diet and the negative MIND-AD trial

6.4.10 Sodium reduction and the SSaSS salt-substitute trial

6.4.11 Cognitive training and the ACTIVE trial

6.4.12 Sleep hygiene as a vascular intervention

6.4.13 Priority 5 — Build cognitive and social reserve

6.4.14 The ACHIEVE hearing aid trial — 48% reduction in cognitive decline

6.4.15 Priority 6 — Address the smaller but real items

6.4.16 The future: better measurement, risk stratification, earlier intervention

6.4.17 Why prevention works the way it works